CN102803508B - 用于干细胞成像的组合物和方法 - Google Patents
用于干细胞成像的组合物和方法 Download PDFInfo
- Publication number
- CN102803508B CN102803508B CN201080051618.0A CN201080051618A CN102803508B CN 102803508 B CN102803508 B CN 102803508B CN 201080051618 A CN201080051618 A CN 201080051618A CN 102803508 B CN102803508 B CN 102803508B
- Authority
- CN
- China
- Prior art keywords
- cell
- nucleotide sequence
- expression
- sequence
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 71
- 238000003384 imaging method Methods 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title abstract description 26
- 239000000203 mixture Substances 0.000 title description 3
- 230000014509 gene expression Effects 0.000 claims abstract description 146
- 239000002773 nucleotide Substances 0.000 claims abstract description 140
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 140
- 230000033228 biological regulation Effects 0.000 claims abstract description 91
- 239000013604 expression vector Substances 0.000 claims abstract description 78
- 108091027981 Response element Proteins 0.000 claims abstract description 72
- 238000012360 testing method Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 207
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 claims description 56
- 102100021380 Transcription factor GATA-4 Human genes 0.000 claims description 46
- 235000018102 proteins Nutrition 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 238000012544 monitoring process Methods 0.000 claims description 21
- 238000002600 positron emission tomography Methods 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 11
- 238000003146 transient transfection Methods 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 6
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 210000002444 unipotent stem cell Anatomy 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000002779 inactivation Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 67
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 40
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 239000005089 Luciferase Substances 0.000 description 26
- 108060001084 Luciferase Proteins 0.000 description 24
- 238000001890 transfection Methods 0.000 description 24
- 108010052090 Renilla Luciferases Proteins 0.000 description 23
- 230000004069 differentiation Effects 0.000 description 23
- 102000044159 Ubiquitin Human genes 0.000 description 20
- 108090000848 Ubiquitin Proteins 0.000 description 20
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 108700008625 Reporter Genes Proteins 0.000 description 16
- 102000006830 Luminescent Proteins Human genes 0.000 description 12
- 108010047357 Luminescent Proteins Proteins 0.000 description 12
- 238000012408 PCR amplification Methods 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 102100036646 Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Human genes 0.000 description 8
- 101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 241000021375 Xenogenes Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000002064 heart cell Anatomy 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000002608 intravascular ultrasound Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 102000008857 Ferritin Human genes 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- -1 RFP Chemical compound 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LYSDZXGDWHEQSY-KZXKDKCNSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1.O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LYSDZXGDWHEQSY-KZXKDKCNSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100034787 Cell cycle exit and neuronal differentiation protein 1 Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000945882 Homo sapiens Cell cycle exit and neuronal differentiation protein 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100067759 Mus musculus Gast gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 241000242743 Renilla reniformis Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000013278 single fertilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/555,901 US9719146B2 (en) | 2009-09-09 | 2009-09-09 | Composition and method for imaging stem cells |
US12/555901 | 2009-09-09 | ||
PCT/EP2010/063054 WO2011029798A1 (en) | 2009-09-09 | 2010-09-06 | Composition and method for imaging stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102803508A CN102803508A (zh) | 2012-11-28 |
CN102803508B true CN102803508B (zh) | 2015-10-21 |
Family
ID=43034378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080051618.0A Expired - Fee Related CN102803508B (zh) | 2009-09-09 | 2010-09-06 | 用于干细胞成像的组合物和方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9719146B2 (zh) |
EP (1) | EP2475780B1 (zh) |
JP (1) | JP6106436B2 (zh) |
KR (1) | KR101760533B1 (zh) |
CN (1) | CN102803508B (zh) |
AU (1) | AU2010294316B2 (zh) |
CA (1) | CA2773624C (zh) |
IN (1) | IN2012DN01992A (zh) |
SG (1) | SG179561A1 (zh) |
WO (1) | WO2011029798A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5860805B2 (ja) * | 2010-03-23 | 2016-02-16 | オリンパス株式会社 | 幹細胞の分化状態をモニタリングする方法 |
US20130137604A1 (en) * | 2011-11-30 | 2013-05-30 | Raytheon Bbn Technologies Corp. | Methods of evaluating genetic elements |
US9719127B2 (en) * | 2012-03-20 | 2017-08-01 | The Regents Of The University Of California | Dual inducible vectors and cell lines |
AU2013264708B2 (en) * | 2012-05-23 | 2019-03-07 | Kyoto University | Highly efficient method for establishing artificial pluripotent stem cell |
JP6116226B2 (ja) * | 2012-06-11 | 2017-04-19 | オリンパス株式会社 | 幹細胞の状態を同定する方法 |
JP2014176364A (ja) * | 2013-03-15 | 2014-09-25 | Olympus Corp | 幹細胞の解析方法 |
JP6223037B2 (ja) * | 2013-07-22 | 2017-11-01 | オリンパス株式会社 | サバイビンについての細胞解析方法、並びにそれを利用した癌の解析方法および薬効のスクリーニング方法 |
JP6454478B2 (ja) | 2013-09-12 | 2019-01-16 | オリンパス株式会社 | 心筋細胞への分化をモニタリングする方法 |
US20180363070A9 (en) * | 2014-08-12 | 2018-12-20 | Univ Wayne State | Systems and methods to detect stem cell stress and uses thereof |
WO2018122932A1 (ja) * | 2016-12-26 | 2018-07-05 | オリンパス株式会社 | 細胞の選別方法、純化された細胞集団の製造方法、及び発光イメージングシステム |
US11124847B1 (en) * | 2017-10-03 | 2021-09-21 | Nzumbe, Inc. | Systems and methods for assessing perturbations in cellular differentiation using reporter cell lines |
WO2020243660A1 (en) * | 2019-05-30 | 2020-12-03 | 490 BioTech, Inc. | Lux expression in cells and methods of use |
CN114164233A (zh) * | 2021-11-05 | 2022-03-11 | 贵州医科大学附属医院 | 一种pProTG质粒、其构建方法及应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008776B1 (en) * | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
DE19710643A1 (de) * | 1997-03-14 | 1998-09-17 | Hoechst Ag | Der Promotor des cdc25B Genes und seine Verwendung in der Gentherapie |
US6482937B1 (en) * | 1997-10-09 | 2002-11-19 | Biotransplant, Inc. | Porcine Oct-4 promoter |
WO2001051006A2 (en) * | 2000-01-14 | 2001-07-19 | Beth Israel Deaconess Medical Center | Cardiac-cell specific enhancer elements and uses thereof |
US20030044976A1 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
WO2003070965A2 (en) * | 2002-02-15 | 2003-08-28 | The Johns Hopkins University | The eaat2 promoter and uses thereof |
US7399851B2 (en) * | 2002-07-25 | 2008-07-15 | Dana Farber Cancer Institute, Inc. | Composition and method for imaging cells |
WO2004081189A2 (en) * | 2003-03-07 | 2004-09-23 | Stanford University | Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and organisms |
ATE381620T1 (de) | 2003-04-24 | 2008-01-15 | San Raffaele Centro Fond | Synthetische bidirektionale promotoren und deren verwendungen |
US20050101017A1 (en) * | 2003-11-10 | 2005-05-12 | Wojtek Auerbach | Method of improving gene targeting using a ubiquitin promoter |
US7682828B2 (en) * | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
CN1910159A (zh) * | 2004-01-16 | 2007-02-07 | 诺瓦提斯公司 | 2,4-二氨基嘧啶和它们用于诱导心肌发生的用途 |
US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
AU2007257180A1 (en) | 2006-06-08 | 2007-12-13 | Multi-Magnetics Incorporated | Magnetosome gene expression in eukaryotic cells |
WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
US7972849B2 (en) * | 2007-05-17 | 2011-07-05 | Oregon Health & Science University | Primate pluripotent stem cells produced by somatic cell nuclear transfer |
WO2008144052A2 (en) | 2007-05-18 | 2008-11-27 | Rampyari Walia | Bioluminescent imaging of stem cells |
US20090137023A1 (en) * | 2007-10-16 | 2009-05-28 | Brandon John Casutt | Cytoplasm of Eukaryotic cells for reprogramming of somatic cells, healing, repairing and therapeutic applications |
KR100952368B1 (ko) | 2007-11-29 | 2010-04-09 | 고려대학교 산학협력단 | 이중 프로모터 리포터유전자 발현 시스템 및 이를 이용한심근세포 및 혈관내피세포 분화를 동시에 모니터링하는방법 |
-
2009
- 2009-09-09 US US12/555,901 patent/US9719146B2/en active Active
-
2010
- 2010-09-06 EP EP10751929.0A patent/EP2475780B1/en not_active Not-in-force
- 2010-09-06 KR KR1020127008915A patent/KR101760533B1/ko active IP Right Grant
- 2010-09-06 WO PCT/EP2010/063054 patent/WO2011029798A1/en active Application Filing
- 2010-09-06 JP JP2012528336A patent/JP6106436B2/ja not_active Expired - Fee Related
- 2010-09-06 SG SG2012016390A patent/SG179561A1/en unknown
- 2010-09-06 CN CN201080051618.0A patent/CN102803508B/zh not_active Expired - Fee Related
- 2010-09-06 AU AU2010294316A patent/AU2010294316B2/en not_active Ceased
- 2010-09-06 IN IN1992DEN2012 patent/IN2012DN01992A/en unknown
- 2010-09-06 CA CA2773624A patent/CA2773624C/en not_active Expired - Fee Related
-
2017
- 2017-06-23 US US15/631,124 patent/US10920287B2/en active Active
Non-Patent Citations (3)
Title |
---|
"A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal";Pan G;《FASEB J.》;20060621;第20卷(第10期);摘要 * |
"Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector";Jun Tian;《Gene Ther.》;20090514;第16卷(第7期);第2页第3段,第4页最后1段,图1、6 * |
"Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells";Yu X;《Mol Ther.》;20030630;第7卷(第6期);827-838 * |
Also Published As
Publication number | Publication date |
---|---|
SG179561A1 (en) | 2012-05-30 |
US20110059439A1 (en) | 2011-03-10 |
KR20120089667A (ko) | 2012-08-13 |
AU2010294316A1 (en) | 2012-03-22 |
WO2011029798A1 (en) | 2011-03-17 |
US10920287B2 (en) | 2021-02-16 |
IN2012DN01992A (zh) | 2015-07-24 |
JP6106436B2 (ja) | 2017-03-29 |
KR101760533B1 (ko) | 2017-07-21 |
CN102803508A (zh) | 2012-11-28 |
JP2013503648A (ja) | 2013-02-04 |
US20170298455A1 (en) | 2017-10-19 |
EP2475780A1 (en) | 2012-07-18 |
EP2475780B1 (en) | 2015-03-04 |
CA2773624C (en) | 2019-07-30 |
US9719146B2 (en) | 2017-08-01 |
CA2773624A1 (en) | 2011-03-17 |
AU2010294316B2 (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102803508B (zh) | 用于干细胞成像的组合物和方法 | |
Abranches et al. | Generation and characterization of a novel mouse embryonic stem cell line with a dynamic reporter of Nanog expression | |
Hohenstein et al. | Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells | |
WO2010012077A1 (en) | Compositions, methods and kits for reprogramming somatic cells | |
Xie et al. | Genetic modification of embryonic stem cells with VEGF enhances cell survival and improves cardiac function | |
US10793921B2 (en) | Low-leakage cellular biosensor system | |
Xie et al. | Long noncoding RNA lnc-NAP sponges mmu-miR-139-5p to modulate Nanog functions in mouse ESCs and embryos | |
EP3733850A1 (en) | Chimeric promoter with high transcriptional activity in t-cells | |
JP6822837B2 (ja) | 膵内分泌細胞及びその製造方法、並びに分化転換剤 | |
Trautsch et al. | Optogenetic monitoring of the glutathione redox state in engineered human myocardium | |
US20210214732A1 (en) | Lux expression in cells and methods of use | |
US20210238555A1 (en) | Method for producing pancreatic endocrine cells | |
CN114729361B (zh) | 一种在活化的t细胞中具有高活性的启动子 | |
CN101671666A (zh) | 用于恶性肿瘤基因治疗的增殖和肿瘤细胞特异性基因操纵系统 | |
Wilson et al. | Bioluminescence reporter gene imaging of human embryonic stem cell survival, proliferation, and fate | |
Daly et al. | Pituitary tumors and immortalized cell lines generated by cre-inducible expression of SV40 T antigen | |
US20240093206A1 (en) | System of stable gene expression in cell lines and methods of making and using the same | |
Liu et al. | Predator: A novel method for targeted protein degradation | |
KR101117422B1 (ko) | 줄기세포의 분화능 평가방법 | |
CN103421831B (zh) | 用于提高体外培养人肝细胞的生理性cyp3a4表达的嵌合基因及其构建方法 | |
CN108575911B (zh) | 一种人组成型雄烷受体转基因小鼠模型的构建方法及其肝细胞应用 | |
Tanaka et al. | Ephrin Forward Signaling Controls Interspecies Cell Competition in Pluripotent Stem Cells | |
Adusumalli et al. | Spatiotemporal Transcriptomes of Pig Hearts Reveal Midkine-Mediated Vascularization in a Chronic Myocardial Infarcted Model | |
Rakhra et al. | Generation of a tetracycline regulated mouse model of MYC-induced T-cell acute lymphoblastic leukemia | |
KR20130042274A (ko) | 발광과 형광을 동시에 측정할 수 있는 전립선 암세포주 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UN Effective date: 20150522 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150522 Address after: American New York Applicant after: General Electric Co. Applicant after: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University Applicant after: Qingbei National University Industrial Academic Cooperation Foundation Address before: American New York Applicant before: General Electric Co. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210112 Address after: England Patentee after: Global life science solutions UK Ltd. Patentee after: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University Patentee after: Qingbei National University Industrial Academic Cooperation Foundation Address before: British platinum County Patentee before: GE HEALTHCARE UK Ltd. Patentee before: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University Patentee before: Qingbei National University Industrial Academic Cooperation Foundation Effective date of registration: 20210112 Address after: British platinum County Patentee after: GE HEALTHCARE UK Ltd. Patentee after: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University Patentee after: Qingbei National University Industrial Academic Cooperation Foundation Address before: New York State, USA Patentee before: General Electric Co. Patentee before: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR University Patentee before: Qingbei National University Industrial Academic Cooperation Foundation |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151021 Termination date: 20210906 |